Company intelligence / Profile preview
Innocoll
Princeton, New Jersey, USAinnocoll.com ↗
- Ownership
- Private
- Employees
- ~73
- Development stage
- Other
01
Overview
Innocoll has developed and commercialized collagen-based drug delivery implants such as XARACOLL for postsurgical pain. Their pipeline includes late-stage assets focused on improving patient outcomes in surgical settings. The company emphasizes targeted drug delivery using proprietary collagen technology. Clinical results have led to FDA approval for at least one product.
- Therapeutic areas
- Other
- Modalities
- Collagen-based drug delivery systemsSmall molecules (e.g., bupivacaine HCl)
- Industry
- Biotech
02
Drug pipeline
20 assets19 more assets in the full pipeline.
Beyond the preview
Go deeper on Innocoll.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Innocoll.